Major Depressive Disorder Treatment Guidelines in America and Europe

ArticleinThe Journal of Clinical Psychiatry 71 Suppl E1(suppl E1):e04 · March 2010with641 Reads
DOI: 10.4088/JCP.9058se1c.04gry · Source: PubMed
Abstract
The various major American and European guidelines for the treatment of depression provide similar basic principles of treatment, which include individualizing the treatment plan, preparing the patient for potential long-term treatment, providing measurement-based care, and treating to remission. While the guidelines are all evidence-based, certain factors can influence differences in specific recommendations, such as the consensus group's composition, underlying mandates, and cultural attitudes. The similarities and differences among 6 sets of guidelines from Europe and the Americas published in the past decade are reviewed here (American Psychiatric Association, British Association for Psychopharmacology, Canadian Network for Mood and Anxiety Treatments, National Institute for Health and Clinical Excellence, Texas Medication Algorithm Project, and World Federation of Societies of Biological Psychiatry). In the guidelines, mild depression has the most variance in treatment recommendations; some, but not all, guidelines suggest that it may resolve with exercise or watchful waiting, but psychotherapy or antidepressants could be used if initial efforts fail. Moderate and severe major depression carry broadly similar recommendations among the guidelines. First-line treatment recommendations for moderate major depressive disorder include antidepressant monotherapy, psychotherapy, and the combination of both. Severe depression may require the combination of an antidepressant and an antipsychotic, electroconvulsive therapy, or the combination of an antidepressant and psychotherapy. Benzodiazepines play a very limited role in the treatment of depression; if the patient has catatonic depression, acutely suicidal depression, or depression with symptoms of anxiety, agitation, or insomnia, benzodiazepines are recommended by some guidelines for short-term treatment only.
    • "Treatments for episodes of major depressive disorders usually last between 6 months and 1 year. Antipsychotics are required for severe depressions with psychotic symptoms until these symptoms are controlled [4]. More infrequently, drug combinations, electroconvulsive therapy, transcranial magnetic stimulation, vagus nerve stimulation, or deep brain stimulation, among other techniques, may be necessary in cases of treatment-refractory depression [5]. "
    [Show abstract] [Hide abstract] ABSTRACT: Mood is the overall affective quality that is based on how the individual experiences the world and themselves in a given time or period. It is the affective tone of this experience. Typically, the states of mood fluctuate according to internal or external, objective or subjective events within a certain range compatible with such events, and these oscillations are inherent to events. Therefore, mood swings can be considered normal. However, they can also occur for pathological reasons and represent a significant change in the functioning of the affected person. When mood swings are pathological, they lose the quantitative and qualitative proportionality in relation to the events that would have promoted them and are no longer explained by them. Furthermore, these oscillations can arise spontaneously, without association with any event; they can be durable and disruptive and can destabilize the individuals and their relationship with the world. Mood disorders can occur in several mental disorders but are more common in depressive and bipolar disorders.
    Full-text · Chapter · Jan 2016 · Frontiers in Human Neuroscience
    • "Regardless, AS appears to limit multimodal outcome for youth with OCD and may partially explain why multimodal treatment for OCD is not consistently more advantageous than CBT-ERP alone (Foa et al., 2005; Ivarsson et al., 2015; Storch et al., 2013). Research seeking to better understand how AS impacts multimodal treatment outcome is needed, especially in other pediatric populations beyond OCD where multimodal treatment is common (e.g., Davidson et al., 2010; Walkup et al., 2008). Some have mentioned that starting multimodal treatments simultaneously versus sequentially may result in worse outcomes (Petersen, 2006); our results were observed despite the recommended sequential initiation of treatment. "
    [Show abstract] [Hide abstract] ABSTRACT: Abstract Objective Activation Syndrome (AS) is a side-effect of antidepressants consisting of irritability, mania, self-harm, akathisia, and disinhibition. The current study was conducted to analyze how AS may hinder treatment outcome for multimodal treatment for children and adolescents with Obsessive-Compulsive Disorder. Methods Fifty-six children or adolescents were recruited at two treatment sites in a double-blind randomized-controlled trial where participants received Cognitive-Behavioral Therapy and were randomized to slow titration of sertraline, regular titration of sertraline or placebo. Results Using a recently developed measure of AS, results suggested that higher average levels of all five AS symptom clusters significantly interfered with treatment response and explained 18% of the variance in obsessive-compulsive symptoms during treatment. Interestingly, only session-to-session increases in irritability resulted in a session-to-session increase in obsessive-compulsive symptoms. The observed results were unchanged with the addition of SSRI dosage as a covariate. Conclusions Results provide empirical support for the proposed hypothesis that AS may hinder multi-modal treatment outcome for pediatric OCD. These findings suggest that dosage changes due to AS do not explain why those with higher AS had worse multi-modal outcome. Other possible mechanisms explaining this observed disruption are proposed, including how AS may interfere with Cognitive-Behavioral Therapy.
    Full-text · Article · Oct 2015
    • "However, this review considered only peripheral or bloodbased biomarkers used in current clinical practice due to their comparative non-invasive nature and ease of measurement. The uncertainty surrounding management decisions in patients with depression in current practice is a particular issue at the time of initial presentation (Davidson, 2010). Hence, this review was focussed on addressing the issue of the use of peripheral biomarkers at baseline or pre-treatment as a predictive tool of clinical outcome (both mental and physical) and not on assessing changes in a peripheral biomarker level following treatment for depression. "
    [Show abstract] [Hide abstract] ABSTRACT: Depression is one of the major global health challenges and a leading contributor of health related disability and costs. Depression is a heterogeneous disorder and current methods for assessing its severity in clinical practice rely on symptom count, however this approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is particularly challenging in primary care, where the majority of patients with depression are managed, due to the presence of co-morbidities. Current methods for risk assessment of depression do not accurately predict treatment response or clinical outcomes. Several biological pathways have been implicated in the pathophysiology of depression; however, accurate and predictive biomarkers remain elusive. We conducted a systematic review of the published evidence supporting the use of peripheral biomarkers to predict outcomes in depression, using Medline and Embase. Peripheral biomarkers in depression were found to be statistically significant predictors of mental health outcomes such as treatment response, poor outcome and symptom remission; and physical health outcomes such as increased incidence of cardiovascular events and deaths, and all-cause mortality. However, the available evidence has multiple methodological limitations which must be overcome to make any real clinical progress. Despite extensive research on the relationship of depression with peripheral biomarkers, its translational application in practice remains uncertain. In future, peripheral biomarkers identified with novel techniques and combining multiple biomarkers may have a potential role in depression risk assessment but further research is needed in this area.
    Full-text · Article · Feb 2015
Show more

    Recommended publications

    Discover more